Now, a device to kill coronavirus — this Bengaluru manufacturer gets approval from FDA, EU
It has been proven to be 99.9 percent effective in neutralising the Spike-Protein or S-protein that are present in coronavirus.
Scalene Hypercharge Corona Canon (Shycocan), a device with the ability to contain the spread of coronavirus, has received approvals from the US Food and Drug Administration (FDA) and the European Union (EU). It is developed by a Bengaluru-based organisation called De Scalene, News18 reported.
Shycocan is built like a small drum that can be fit into offices, schools, malls, hotels, airports, or any closed area for disinfecting surfaces. It is proven to be 99.9 percent effective in neutralising the Spike-Protein or S-protein that are present in coronavirus.
While it cannot cure an infected person, it is highly effective in containing the spread of the deadly virus, the report said.
The device floods a room or any indoor place with hundreds of electrons. So even if an infected individual were to walk into the room, these electrons would neutralise the potency of the virus present in aerosols while sneezing or coughing.
It can also neutralise the virus present on surfaces, thus bringing down transmission via air or surface.
Speaking to News18, Dr. Rajah Vijay Kumar said that they have received clearance from the US FDA under an enforcement directive for COVID-19 health emergencies. As for the EU, they have received the Conformite' Europeene or the certificate of conformity for which Shycocan was put through nearly 26 tests.
The tests include safety, efficacy, testing to determine whether the device has any harmful effects or if it interferes with the working of other devices. It also included tests to assess whether other devices deployed in any place would interfere with the performance of Shycocan.
According to officials, approval for manufacturing came in last week. Kumar also said that the cost and manufacturing will be depending on licence holders, adding that in India, about nine companies have shown interest in manufacturing Shycocan and three companies have entered into a licensing agreement, the report said.